-
-
-
-
-
-
-
Vir Biotechnology (VIR) PT Raised to $18 at Evercore ISI
-
-
-
-
-
-
-
Vir Biotechnology grants Norgine exclusive license for hepatitis delta treatment
-
-
-
-
-
-
-
Vir Biotechnology Inc. (VIR) Misses Q2 EPS by 10c, provides guidance
-
-
-
-
-
-
-
Vir Biotechnology Inc. (VIR) Announces CTO Departure
-
-
-
-
-
-
-
Vir Biotechnology (VIR) Receives FDA Breakthrough Therapy Designation and EMA PRIME Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta
-
-
-
-
-
-
-
Vir Biotechnology (VIR) Appoints Jason O’Byrne as CFO
-
-
-
-
-
-
-
Vir Biotechnology (VIR) Receives FDA IND Clearance and Fast Track Designation for Tobevibart and Elebsiran for the Treatment of Chronic Hepatitis Delta Infection
-
408,535 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

